RxDoctor Payments Data

Aaron Pomajzl, MD

Urology · Lincoln, NENPI 1932550084

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,639 of the $8,823 with a category attached, or 63.9%. Angiodynamics, Inc. accounts for 63.9% of it on its own, with 43 other manufacturers making up the rest. 2025 is the largest year on record at $6,385, more than ten times the $264 reported in 2019.

$8,823in general payments, 2019–2025

Across 148 payments — averaging $59.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$6K
  • Sumitomo Pharma America, Inc.$487
  • Accord Healthcare, Inc.$300
  • Astellas Pharma US Inc$299
  • Johnson & Johnson$226
  • Myovant Sciences Inc.$195
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$2,80532%
  • Education$3794%
  • Other$5,63964%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,823 in reported general payments places this provider in the 75th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$234,107
Medicare patients
520
Services billed
4,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide26$341,671
ErleadaApalutamide11$144,449
MyrbetriqMirabegron64$36,569
Tamsulosin Hcl554$9,384
GemtesaVibegron15$8,456
Trospium Chloride99$5,409
Finasteride258$3,565
Estradiol22$1,437
NitrofurantoinNitrofurantoin Macrocrystal45$1,309
Dutasteride12$713
Solifenacin Succinate12$554
Alfuzosin Hcl ErAlfuzosin Hcl19$547
Tolterodine Tartrate13$520
Trospium Chloride ErTrospium Chloride11$512
Silodosin12$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$299$378,24190 claims
Johnson & JohnsonErleada$226$144,44911 claims
Sumitomo Pharma America, Inc.Gemtesa$487$8,45615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 79 urology providers in Nebraska.

Other urology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →